Reimbursement Scheme Veoza®

Reimbursement Scheme for VEOZA^® (fezolinetant) 45 mg for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Vasomotor symptoms are also known as hot flushes or night sweats.

The health insurance company does currently not reimburse VEOZA^® (fezolinetant) 45 mg for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Therefore, the manufacturer of this medication has requested TBR Netherlands to reimburse patients once for the full costs, product, and dispensing fees.  

Conditions:

Patients can make use of this Reimbursement Scheme only once.

This gives both patients and doctors the opportunity to assess whether treatment with VEOZA^® is suitable for the individual patient in treating moderate to severe vasomotor symptoms (VMS) related to menopause. After one month of treatment, patients and doctors can jointly decide whether they want to continue treatment, taking into account efficacy, tolerance and cost.

Who can claim:

Pharmacists can claim this medication on behalf of the patient. This can only be done online. Alternatively, the patient can submit a digital claim via www.terugbetaalregeling.nl.

For more information check out the Veoza® 45mg medicine page

^{MAT-NL-VEO-2024-00047}